We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ALC:SIXAlcon AG Analysis

Data as of 2026-03-10 - not real-time

$81.85

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Alcon Inc. (ALC) is trading around its 20‑day and 50‑day moving averages with a neutral trend and an RSI hovering near the midpoint, suggesting limited short‑term momentum. The MACD shows a bearish histogram, while price sits above a solid support near $78 and below resistance around $88, framing a modest upside potential of roughly 15% according to the model. Volatility over the past month is elevated at over 24%, yet the stock’s beta of ~0.74 points to lower systematic risk, and the market sentiment index reads “Extreme Greed,” indicating bullish sentiment may be overstretched.
Fundamentally, the company posts a trailing P/E well above the industry average, but a forward P/E near 21 and a modest forward EPS outlook soften the valuation concerns. The dividend yield is low at around 0.4% with a payout ratio under 20%, underscoring a sustainable payout backed by healthy operating and free cash flow. Upcoming Q4 earnings estimates and recent analyst coverage (median target ~$97) provide a catalyst, while the DCF‑derived fair value suggests the stock is not dramatically mispriced. Taken together, the balance of technical neutrality, growth‑oriented fundamentals, and a sustainable dividend supports a cautiously optimistic outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Technical indicators are neutral with limited momentum
  • Upcoming earnings could swing sentiment
  • Current valuation is near fair value

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward earnings growth and improving forward P/E
  • Sustainable dividend with low payout ratio
  • Upside potential of ~15% based on valuation model

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong franchise in surgical and vision care markets
  • Demographic tailwinds for eye‑care products
  • Robust cash generation supporting reinvestment and dividends

Key Metrics & Analysis

Financial Health

Revenue Growth8.60%
Profit Margin9.42%
P/E Ratio41.3
ROE4.50%
ROA2.57%
Debt/Equity23.81
P/B Ratio1.8
Op. Cash Flow$2.3B
Free Cash Flow$1.2B
Industry P/E25.4

Technical Analysis

TrendNeutral
RSI48.7
Support$77.95
Resistance$87.64
MA 20$82.49
MA 50$80.97
MA 200$81.29
MACDBearish
VolumeStable
Fear & Greed Index77.41

Valuation

Fair Value$41.98
Target Price$94.41
Upside/Downside15.34%
GradeFair
TypeBlend
Dividend Yield0.41%

Risk Assessment

Beta0.74
Volatility24.35%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.